Catalent (CTLT) Lowered to Hold at Zacks Investment Research
Catalent (NYSE:CTLT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other equities analysts have also recently issued reports about the stock. ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Bank of America lifted their price target on shares of Catalent from $47.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Royal Bank of Canada set a $48.00 price objective on shares of Catalent and gave the company a “buy” rating in a research report on Monday, February 5th. Goldman Sachs started coverage on shares of Catalent in a research report on Wednesday, January 24th. They issued a “buy” rating and a $50.00 price objective for the company. Finally, First Analysis started coverage on shares of Catalent in a research report on Friday, January 5th. They issued an “equal weight” rating for the company. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $45.64.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, February 5th. The company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The firm had revenue of $606.30 million during the quarter, compared to analysts’ expectations of $565.05 million. During the same period in the previous year, the company earned $0.27 EPS. The firm’s revenue for the quarter was up 25.3% compared to the same quarter last year. analysts predict that Catalent will post 1.53 earnings per share for the current year.
In other Catalent news, SVP William Downie sold 9,082 shares of the business’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $41.80, for a total value of $379,627.60. Following the completion of the sale, the senior vice president now directly owns 46,986 shares of the company’s stock, valued at approximately $1,964,014.80. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.70% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of CTLT. Nationwide Fund Advisors raised its holdings in shares of Catalent by 18.4% in the 3rd quarter. Nationwide Fund Advisors now owns 382,620 shares of the company’s stock valued at $15,274,000 after purchasing an additional 59,528 shares in the last quarter. Crossmark Global Holdings Inc. bought a new stake in shares of Catalent in the 3rd quarter valued at about $451,000. Victory Capital Management Inc. bought a new stake in shares of Catalent in the 3rd quarter valued at about $1,182,000. Principal Financial Group Inc. raised its holdings in shares of Catalent by 4.0% in the 3rd quarter. Principal Financial Group Inc. now owns 558,754 shares of the company’s stock valued at $22,305,000 after purchasing an additional 21,356 shares in the last quarter. Finally, Jennison Associates LLC bought a new stake in shares of Catalent in the 3rd quarter valued at about $303,000. Institutional investors and hedge funds own 99.89% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Catalent (CTLT) Lowered to Hold at Zacks Investment Research” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/catalent-ctlt-lowered-to-hold-at-zacks-investment-research/1954823.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.